APOE

Apolipoprotein E

Score: 0.638 Price: $0.64 Medium Druggability Status: active Wiki: APOE

🔴 Alzheimer's Disease 🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

3085

DEBATES

3D Protein Structure

🧬 APOE — PDB 3R4L Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Medium

Score: 0.47

Clinical Stage

Phase II

Target Class

Ligand

Safety

0.40

Druggability Analysis

Drug Development0.35

Structural Tractability0.85

Target Class0.50

Safety Profile0.40

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (4 compounds)

1 Phase II · 3 Preclinical

Therapeutic Areas:

Alzheimer's disease Mild cognitive impairment (MCI) Neuroinflammation Cerebral amyloid angiopathy Apolipoprotein E4-related neurodegeneration Cardiovascular disease with cognitive impairment

Druggability Rationale: APOE presents moderate druggability (0.55) despite being a challenging target due to its intrinsically disordered nature and protein-protein interaction mechanism. However, 15 available PDB structures (best resolution 1.4 Å) and successful Phase 2 clinical progress with CN-105 demonstrate that tractable binding pockets exist, particularly for lipid-binding domains and protein interaction interfaces that can be targeted by peptides, small molecules, and biologics.

Mechanism: Protein-protein interaction modulator or lipid metabolism enhancer

Drug Pipeline (4 compounds)

1 Phase II · 3 Preclinical

Known Drugs:

ApoE mimetic peptides (preclinical)

CN-105 (phase_2)

APOE gene therapy vectors (preclinical)

Small molecule APOE modulators (preclinical)

Structural Data:

PDB (15) ✓AlphaFold ✓Cryo-EM ✓

1YA9 2KC3 2L7B 6IWB 6NCN+10 more

UniProt: A0A0S2Z3D5

Binding Pocket Analysis:

APOE contains a well-characterized lipid-binding pocket in the N-terminal domain (residues 1-191) that accommodates phospholipids and cholesterol, alongside a dynamic C-terminal domain involved in apoB receptor binding. The 1.4 Å resolution structures reveal allosteric sites suitable for modulators that can stabilize conformations promoting amyloid clearance or alter lipidation states without abolishing native function.

🧬 3D Protein Structure

🧬 APOE — PDB 3R4L Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

A critical selectivity challenge involves discriminating between APOE isoforms (E2, E3, E4), where E4-selective modulation is therapeutically desired but structurally demanding due to limited sequence divergence. Off-target effects on systemic lipid metabolism and hepatic APOE function must be carefully managed to avoid peripheral toxicity, particularly for brain-penetrant small molecules.